Acil Serviste Akut Stroke Tanısı Alan Hastaların Kullandığı Antikoagülan ve Antiagregan İlaçların Araştırılması

Öz

Amaç: Bu çalışma ile iskemik inme tanısı almış olan hastaların özgeçmişlerinde kullanmış oldukları antikoagülan&antiagregan ilaçların analizinin yapılması amaçlanmıştır. Gereç ve Yöntemler: Çalışmamız Kayseri Şehir Hastanesi Acil Servisinde retrospektif olarak yapıldı. 01.01.2024-31.12.2024 tarihleri arasında başvurmuş 18 yaş üstü akut iskemik inme tanısı alıp takip edilmiş hastalar ile yapıldı. 302 hasta ile çalışma tamamlandı. Araştırma için hastaların demografik verileri (yaş, cinsiyet), ek hastalıkları, kullanmış oldukları ilaçları kaydedilip klinik sonlanımları araştırıldı. Bulgular: Çalışmaya dahil edilen toplam 302 hastanın yaş ortanca değeri 72 (IQRs: 62- 79, min:30 max:97) yıldı. Hastaların %52,3’ ü (n= 158) erkek %47,7’ si (n=144) kadındı. Hastaların %11,9’ unda (n=36) atriyal fibrilasyon öyküsü varken hastaların %32,1’ i (n=97) antiplatelet veya antikoagülan bir ajan kullanım öyküsü vardı. Hastaların %14,2’ si (n=43) asetilsalisilik asit, %7,3’ ü (n=22) klopidogrel ve %10,6’ sı (n=32) oral antikoagülan ajan kullanıyordu. Hastaların kullandığı antiplatelet, antiagregan veya antikoagülan ajan açısından hastane içi mortalite incelendiğinde istatistiksel anlamlı farklılık edildi (p= 0,012). Sonuç: Buna göre asetilsalisilik asit kullanan hastalarda ölüm oranı klopidogrel ve oral antikoagülana göre daha düşüktü.

Anahtar Kelimeler

• İnme
• antikoagülan ilaçlar
• mortalite

Investigation of Anticoagulant and Antiaggregant Drugs Used by Patients Diagnosed with Acute Stroke in the Emergency Department

Öz

Aim: The aim of this study was to analyze the anticoagulant & antiaggregant drugs used by patients diagnosed with ischemic stroke in their medical history. Materials and Methods: Our study was conducted retrospectively in the Emergency Department of Kayseri City Hospital. Patients over the age of 18 who were diagnosed with acute ischemic stroke and followed up between 01.01.2024-31.12.2024. The study was completed with 302 patients. Demographic data (age, gender), comorbidities, medications used by the patients were recorded and clinical outcomes were investigated. Results: The median age of the 302 patients included in the study was 72 years (IQRs: 62-79, min:30 max:97). 52.3% (n=158) of the patients were male and 47.7% (n=144) were female. While 11.9% (n=36) of the patients had a history of atrial fibrillation, 32.1% (n=97) of the patients had a history of antiplatelet or anticoagulant agent use. Acetylsalicylic acid was used by 14.2% (n=43), clopidogrel by 7.3% (n=22) and oral anticoagulant agents by 10.6% (n=32). There was a statistically significant difference in in-hospital mortality according to the antiplatelet, antiaggregant or anticoagulant agents used (p= 0.012). Conclusion: Accordingly, the mortality rate was lower in patients using acetylsalicylic acid compared to clopidogrel and oral anticoagulants.

Anahtar Kelimeler

• stroke
• anticoagulant agents
• mortality

Kaynakça

1. 1. Alpaslan M, Baykan N, Oktay M, Salt Ö, Koyuncu S, Bol O, et al. Evaluation of patients diagnosed with thromboembolism in the emergency department before and during the COVID-19 pandemic. Medical Research Archives. 2024;10(12):1-10.
2. 2. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2):635-641.
3. 3. İnce B. Dual antiplatelet therapy in ischemic stroke. Türk Beyin Damar Hast Derg. 2019;25(2):86-93.
4. 4. Alpaslan M, Baykan N. Radiological imaging and analysis of laboratory values in case of acute ischemic stroke. Genel Tıp Derg. 2024;34(2):171-180.
5. 5. Feske, Steven K. Ischemic stroke. The American journal of medicine 2021;134.12:1457-1464.
6. 6. Escudero-Martinez I, Morales-Caba L, Segura T. Atrial fibrillation and stroke: A review and new insights. Trends in cardiovascular medicine. 2023;33(1):23-29.
7. 7. Vinding NE, Kristensen SL, Rørth R, Butt JH, Østergaard L, Olesen JB, et al. Ischemic stroke severity and mortality in patients with and without atrial fibrillation. Journal of the American Heart Association 2022;11(4):e022638.
8. 8. Xian Y, Xu H, O’Brien EC, Shah S, Thomas L, Pencina MJ, et al. Clinical effectiveness of direct oral anticoagulants vs Warfarin in older patients with atrial fibrillation and ischemic stroke: Findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. JAMA Neurology. 2019;76(10):1192–1202.

9. 9. Zeng S, Zheng Y, Jiang J, Ma J, Zhu W, Cai X. Effectiveness and safety of DOACs vs. Warfarin in patients with atrial fibrillation and frailty: A systematic review and meta-analysis. Frontiers in Cardiovascular Medicine 2022;9:907197.